CONNECT WITH US
HealthTech

HealthTech

Tandem Diabetes Care names next CEO

MedTech Dive logo

Published on

Add as a preferred source on Google
Tandem Diabetes Care names next CEO

Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019.

Tandem Diabetes Care said Thursday that Jeannette Bankes will become the company’s next CEO. Bankes will start on Nov. 16 as current CEO John Sheridan plans to retire at the end of the year.

“I’m 70 and I’ve got to make a decision at some point,” Sheridan said in a Thursday earnings call, adding that he and the board had been working together for a while to find a successor. Sheridan said he had confidence in the company’s future under Bankes’ leadership, citing her more than 30 years of operating experience.

Bankes is currently CEO of GE HealthCare’s patient care solutions business, a $3.1 billion business that includes monitoring, diagnostic cardiology and anesthesia products. Bankes drove growth and profitability across the business, according to Tandem’s statement.

Prior to working at GE HealthCare, Bankes was Alcon’s president of global franchises.

Bankes will receive an annual base salary of $900,000, according to Tandem’s latest quarterly filing.

Sheridan joined Tandem as its chief operating officer in 2013. He became CEO in 2019. The outgoing CEO will stay on as an employee through the end of the year and then serve as a consultant.

During his tenure, the diabetes technology firm launched its first hybrid closed-loop technology and introduced a tiny, tubed insulin pump.

Sheridan said he had a list of priorities he cared about before stepping down, such as developing a tubeless insulin pump, starting work on a fully closed loop automated insulin delivery system and developing coverage through the pharmacy channel.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.